Trials / Completed
CompletedNCT04849000
Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage
Phase III, Multicentre, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of SHR-1209 Monotherapy in Patients With Primary Hypercholesterolemia and Mixed Hyperlipemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 709 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The study is ongoing to evaluate the efficacy and safety of SHR-1209 in patients with hypercholesterolemia and hyperlipemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1209 | SHR-1209 |
| DRUG | SHR-1209 Placebo | SHR-1209 Placebo |
Timeline
- Start date
- 2021-04-23
- Primary completion
- 2022-06-21
- Completion
- 2023-01-13
- First posted
- 2021-04-19
- Last updated
- 2023-05-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04849000. Inclusion in this directory is not an endorsement.